DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 18F-DOPA; 1H-Pyrazol; 2S,4R-(-)-ketoconazole; 2S,4R-(-)-ketoconazole, levoketoconazole; ATR-101; AZD4017; AZD4017 and prednisolone; Abiraterone; Abiraterone Acetate; Acetate; Acthrel; Bexarotene; CABERGOLINE; CABERGOLINE TEVA; CI-984; CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE; COR-003; CORT125134; Cabergoline; Calcium; Calcium carbonate; Carbonate; Corticotropin; Corticotropin-releasing hormone; Cushing's syndrome confirmation; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate; Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate; Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe); DDAVP; DOSTINEX; Device: IPC; Device: continuous glucose monitoring; Dexamethasone; Diagnostic Test: 24-hour Urine test; Diagnostic Test: Blood test; Diagnostic Test: CT scan; Diagnostic Test: Dexamethasone test; Diagnostic Test: MRI; Diagnostic Test: Saliva swab; Dostinex; Dotatate; Eplerenone; Gefitinib; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; Glucocorticoids; Glucophage (metformin); Glucose; HRA052015; HRA052015 (mifepristone); Hydrocortisone; Hypro; Insulin; KETOCONAZOLE; Ketoconazole; L0006CP03A; LA; LCI699; LCI699, 1 mg; LCI699, 10 mg; LCI699, 20 mg; LCI699, 5 mg; LMWH/Rivaroxaban; Lapatinib; Levoketoconazole; Levoketozonazole; Liqourice; Liraglutide; METYRAPONE; MIFEPRISTONE; Matyrapone; Metformin; Methionine; Metopirone; Metopirone 250 mg capsules; Metopirone 250 mg capsules/Cormeto; Metyrapone; Mifedren; Mifepristone; NIZORAL; Nevanimibe; Nevanimibe hydrochloride; Nizoral; OROCAL; OSILODROSTAT; OSTEOPOR; Octreotide; Osilodrostat; Osilodrostat 10mg; Osilodrostat 1mg; Osilodrostat 20mg; Osilodrostat 5mg; Ossein hydroxyapatite; Other: Control; Other: Hydrocortisone; Other: Obese; Other: [11C]-Methionine PET/MRI; Ovine Corticotropin-Releasing Hormone (oCRH); PASIREOTIDE; PASIREOTIDE DIASPARTATE; PASIREOTIDE PAMOATE; Pasireotida; Pasireotida 300; Pasireotida 600; Pasireotida 900; Pasireotide; Pasireotide 0.3mg; Pasireotide 0.6 MG/ML; Pasireotide 0.6mg; Pasireotide 0.9 mg; Pasireotide 20mg; Pasireotide 40mg; Pasireotide 60mg; Pasireotide LAR; Pasireotide pamoate; Pasireotide s.c.; Pasireotide sub-cutaneous; Pasireotide with or without cabergoline; Pasireotode; Pentetreotide; Phe; Prednisolone; Procedure: Hypercortisolism; Procedure: Lateral transperitoneal LA; Procedure: Posterior RA; R-roscovitine; RVG 08938; RVG 15375; RVG 18236; Radiation: DOTATATE PET-CT; Radiation: F-DOPA PET CT; Relacorilant; Rivaroxaban; Rosiglitazone; Rosiglitazone maleate; SIGNIFOR; SOM230; SOM230 300µg; SOM230 600µg; SOM230 900µg; SOM230 LAR; SOM230 LAR 10 mg; SOM230 LAR 30 mg; SOM230 LAR, 20 mg; SOM230 s.c.; SOM230, 300micrograms; SOM230, 600 micrograms; SOM230, 900 micrograms; SOM230B; SOMATROPIN; Seliciclib; Signifor; Sitagliptin; Somatropin; Tadalafil; Tretinoin; Trp; Tyr; Valsartan; Vorinostat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-024165-44-DE (EUCTR)	05/08/2011	12/05/2011	An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)	An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape) - Seascape	Cushing’s disease MedDRA version: 14.1;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Cancer [C04]	Trade Name: Signifor Product Name: Signifor Product Code: SOM230 300µg INN or Proposed INN: pasireotide Trade Name: Signifor Product Name: Signifor Product Code: SOM230 600µg INN or Proposed INN: pasireotide Trade Name: Signifor Product Name: Signifor Product Code: SOM230 900µg INN or Proposed INN: pasireotide	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	300	Phase 3	Czech Republic;Greece;Spain;Netherlands;Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2010-024165-44-DE
(EUCTR)

05/08/2011

12/05/2011

An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)

An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape) - Seascape

Cushing’s disease
MedDRA version: 14.1;Level: LLT;Classification code 10011651;Term: Cushing's disease;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Cancer [C04]

Trade Name: Signifor
Product Name: Signifor
Product Code: SOM230 300µg
INN or Proposed INN: pasireotide
Trade Name: Signifor
Product Name: Signifor
Product Code: SOM230 600µg
INN or Proposed INN: pasireotide
Trade Name: Signifor
Product Name: Signifor
Product Code: SOM230 900µg
INN or Proposed INN: pasireotide

Novartis Pharma Services AG

NULL

Not Recruiting

Female: yes
Male: yes

300

Phase 3

Czech Republic;Greece;Spain;Netherlands;Germany